The purpose of this study is to characterize the effect of kidney impairment on the blood
concentrations of PF-06700841 and its major metabolite. Findings from this study will be used
to develop dosing recommendations so that the dose and/or dosing interval may be adjusted
appropriately in the presence of kidney disease.